Clinical Trials

Our retina specialists and fellows are involved in many clinical trials to continue advancing technology and techniques related to this area of medicine 

​

Phase 1 DME-Genentech Roche [Enrollment Open]

A Phase I, Multicenter, Open-label study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of RO7446603 alone and co-administered with aflibercept in patients with Diabetic Macular Edema.

​

Elevatum- Genentech Roche [Enrollment Open]

A Phase IIIB/IV, Multicenter, Open-label, Single-arm study to investigate Faricimab (ro6867461) treatment response in treatment-naïve, underrepresented patients with diabetic macular edema

​

Pagoda GR40550 - Genentech Roche [Enrollment Closed] 

A Phase III, Multicenter, Randomized, visual assessor masked, active comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with Diabetic Macular Edema.   

​

Pavilion GR41675 – Genentech - Roche [Enrollment Closed]

A Phase III, Multicenter, Randomized study of the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranizumab in patients with Diabetic Retinopathy

Rhone-X GR41987 – Genentech - Roche [Enrollment Closed]

A Multicenter, open-Label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Diabetic Macular Edema.

​

Gather2 ISEE2008 –  Iveric Bio [Enrollment Closed]

A Phase 3, multicenter, randomized, double-masked shamcontrolled clinical trial to assess the safety and efficacy of intravitreal administration of Zimura (complement C5 inhibitor) in patients with Geographic Atrophy secondary to Age-Related Macular Degeneration

​

Condor: CRTH258D2301 – Novartis [Enrollment Closed]

Novartis pharmaceuticals trail entitled: A 96-week, two-arm, randomized single-masked, multi-center, Phase III study assessing the efficacy and safety of Brolucizumab 6mg compared to Panretinal Photocoagulation Laser in patients with Proliferative Diabetic Retinopathy.

Balaton – GR41984 - Genentech - Roche [Enrollment Closed]

A Phase III, Multicenter, Randomized, Double-Masked, Active comparator - controlled study to evaluate the efficacy and safety of Faricimab in patients with Macular Edema secondary to Branch Retinal Vein Occlusion 

Comino- GR41986  – Genentech - Roche [Enrollment Closed]

A Phase III, Multicenter, Randomized, Double-Masked, Active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with Macular Edema secondary to Central Retinal or Hemiretinal Vein Occlusion. 

Janssen- Johnson and Johnson [Upcoming Not Yet Enrolling]

A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-Controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
 

​

Upcoming Trials - Coming Soon...

​

Recently Completed Trials

COOL-3 - RecensMedical Inc.

A Randomized, Masked, Controlled Trial Studying the Use of Rapid Cooling Anesthesia for Local Anesthesia among Patients Receiving Intravitreal Injections  

​

YOSEMITE - GR40349- Genentech Roche

A Phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema.

TENAYA - GR40306 - Genentech Roche 

A Phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety faricimab in patients with neovascular age-related macular degeneration. 

COOL-3 - RecensMedical Inc 

A Randomized, Masked, Controlled Trial Studying the Use of Rapid Cooling Anesthesia for Local Anesthesia among Patients Receiving Intravitreal Injections.  

SCORE2 - NIH (National Eye Institute)     2014 – 2016

 Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: a multicenter, prospective, randomized non-inferiority trial of eyes with macular edema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weeks with intravitreal aflibercept every 4 weeks. 2014-2016

​